全新辅助治疗的早期反应与区域性深度高温对于低水平的局部晚期直肠癌:一个单中心的回顾性研究
Nicole Klinge1, Paul Warncke2,3, Griseldis Petzold1
1Department of Radiooncology, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
概括
总的新辅助疗法 (TNT) 与深度高温 (HT) 显示在局部晚期直肠癌 (LARC) 的承诺. 这种组合改善了缓解和降级,具有可控的副作用,支持进一步的研究.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 手术瘤学手术瘤学
背景情况:
- 局部晚期直肠癌 (LARC) 提出了治疗挑战,特别是在低的瘤中.
- 优化新辅助治疗策略对于改善患者的治疗结果和关节的保存至关重要.
- 总的新辅助疗法 (TNT) 是一种不断发展的LARC管理方法.
研究的目的:
- 评估将TNT与区域深度高温 (HT) 结合用于低LARC的可行性和结果.
- 评估TNT加HT对关节保存率的影响.
- 为了确定对瘤反应,降级和整体治疗毒性的影响.
主要方法:
- 在2018年至2023年期间接受治疗的49名低水平LARC患者的回顾性分析.
- 患者接受了TNT,包括化学辐射和每周两次深度HT.
- 评估的结果包括关节的保存,瘤下降阶段和临床完整反应 (cCR) 或病理完整反应 (pCR) 率.
主要成果:
- 观察到令人鼓舞的完全缓解率 (cCR或pCR) 为39%.
- 76%的患者出现了显著的瘤衰退阶段.
- 达到了49%的总体关节保存率,其中31%的关节在手术期间进行了保存. 这种治疗一般都能很好地忍受.
结论:
- 将TNT与区域深层HT相结合,对于低的LARC来说是一个有前途的战略.
- 这种方法增强了瘤反应,完全缓解,并降低了可接受的毒性.
- 需要进一步的前性随机研究来确认HT在LARC新辅助剂协议中的作用.
更多相关视频
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
2.9K
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
1.6K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...